Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Combination DSCG and Reproterol · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | DSCG + Reproterol |
| 2 | ACTIVE_COMPARATOR | DSCG |
| 3 | ACTIVE_COMPARATOR | Reproterol |
| 4 | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| Combination DSCG and Reproterol | DRUG | 1: |
Inclusion Criteria: * Female and male subjects aged 18 - 65 years * Exercise induced asthma with reversible airway obstruction: twice proven EIA defined as maximum decrease in FEV1 against the baseline value of at least 20% (first test results can be obtained during the last 12 months) * Baseline F...
The fixed-dose combination of disodium cromoglycate (DSCG) and reproterol is being studied for exercise-induced asthma. It is designed to protect against bronchoconstriction triggered by physical activity. The combination is a small-molecule therapy delivered as a fixed-dose product and is in Phase 2 development.
Viatris Inc. (ticker: VTRS) is the developer of the fixed-dose combination of disodium cromoglycate and reproterol. Viatris is a global pharmaceutical company, and this asset is part of its respiratory pipeline.
The combination of DSCG and reproterol is in Phase 2 clinical development. One Phase 2 trial has been completed, and no active trials are currently listed. It is an investigational product and has not been approved by the FDA for any indication.
The combination has been evaluated in a single Phase 2 trial, NCT00777348, titled "To Assess the Protective Effect of the Fixed Drug Combination of Disodium Cromoglycate Plus Reproterol." The trial enrolled 62 participants with exercise-induced asthma in Germany. It was randomized, double-blind, and placebo-controlled, and it has been completed.